(Q39333583)

11 September 2017

title

Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. (English)

1 reference

11 September 2017

6

David C Montefiori

1 reference

11 September 2017

Bapi Pahar

1

1 reference

11 September 2017

Mayra A Cantu

2

1 reference

11 September 2017

Wei Zhao

3

1 reference

11 September 2017

Marcelo J Kuroda

4

1 reference

11 September 2017

Ronald S Veazey

5

1 reference

11 September 2017

John D Clements

7

1 reference

11 September 2017

Pyone P Aye

8

1 reference

11 September 2017

Andrew A Lackner

9

1 reference

11 September 2017

Karin Lovgren-Bengtsson

10

1 reference

11 September 2017

Karol Sestak

11

1 reference

11 September 2017

language of work or name

English

0 references

publication date

5 July 2006

1 reference

11 September 2017

1 reference

11 September 2017

volume

24

1 reference

11 September 2017

issue

47-48

1 reference

11 September 2017

page(s)

6839-6849

1 reference

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251...

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

One step forwards, one step back

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Identifying epitopes of HIV-1 that induce protective antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Design of engineered vaccines for systemic and mucosal immunity to HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

The mucosal immune system: primary target for HIV infection and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

AIDS vaccine models: challenging challenge viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

In vivo and in vitro lipidation of recombinant immunogens for direct iscom incorporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Influence of maternal immunity on antibody and T-cell response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

In vitro infection of primate PBMC with simian/human immunodeficiency virus, SHIV(SF33A): correlation to in vivo outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Defining T-cell-mediated immune responses in rotavirus-infected juvenile rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Detection of antigen-specific T cell interferon gamma expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Development and homeostasis of T cell memory in rhesus macaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

7 January 2021

HIV: viral blitzkrieg.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

HIV swiftly guts the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Evidence for early local viral replication and local production of antiviral immunity upon mucosal simian-human immunodeficiency virus SHIV(89.6) infection in Macaca nemestrina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

A rational basis for mucosal vaccination against HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

HIV and SIV CTL escape: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Progress in the development of an HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Immune control of HIV: the obstacles of HLA and viral diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Differential dynamics of CD4(+) and CD8(+) T-lymphocyte proliferation and activation in acute simian immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Distinct cycling CD4(+)- and CD8(+)-T-cell profiles during the asymptomatic phase of simian immunodeficiency virus SIVmac251 infection in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

inferred from DOI database lookup

7 January 2021

based on heuristic

Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.050

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.06.050

1 reference

11 September 2017

1 reference